Skip to search formSkip to main contentSkip to account menu

FASN Inhibitor TVB-2640

Known as: TVB-2640 
An orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity. Upon administration, TVB-2640 binds to and… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AB010. Metabolic disturbance for prostate cancer therapy
Cancer metabolism is emerging with great interest as a therapeutic target for cancer management. Prostate cancer is especially… 
2017
2017
Utjecaj kandidatnih gena FASN i SCD1 na masnokiselinski sastav mlijeka
2016
2016
Povezanost polimorfizma gena FASN s masnokiselinskim sastavom mlijeka
Istraživanje je provedeno kako bi se utvrdila povezanost polimorfizama gena FASN i sastava masnih kiselina u mlijeku kod Holstajn… 
2015
2015
Abstract B13: Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients
TVB-2640 is a potent, reversible and selective fatty acid synthase (FASN) inhibitor currently in Phase 1 in solid tumor patients… 
2015
2015
Abstract 4446: Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis
Inhibition of de novo palmitate synthesis by fatty acid synthase (FASN) is a novel cancer therapeutic approach with strong… 
2015
2015
LATE BREAKING ABSTRACT: Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in…
Background: FASN inhibition is a novel approach to cancer treatment involving the selective disruption of palmitate biosynthesis…